This document is a Corrigendum (a formal correction) for the study titled "Anti-embolism devices therapy to improve the ICU mortality rate of patients with acute myocardial infarction and type II diabetes mellitus," originally published in Frontiers in Cardiovascular Medicine in 2022.
TL;DR
This correction fixes a reporting error in a study evaluating anti-embolism (AE) devices for high-risk ICU patients. It clarifies that AE-device therapy is associated with a ~50% reduction in mortality risk, correcting previous inconsistencies between the text and data tables and ensuring the use of Hazard Ratios (HR) rather than Odds Ratios (OR).
What Problem Does This Paper Address?
The original research investigated whether anti-embolism devices (such as sequential compression devices or compression stockings) improve survival for patients suffering from both acute myocardial infarction (heart attack) and type II diabetes—a population at high risk for venous thromboembolism in intensive care settings.
However, the published version contained a significant clerical error: the data in "Table 2" did not match the text in the Abstract and Results sections. Furthermore, the authors mistakenly used the term "Odds Ratio" (OR) in some sections when the statistical method employed (Cox proportional hazards regression) actually produces "Hazard Ratios" (HR). This corrigendum was issued to synchronize the data and terminology across the entire paper to maintain scientific integrity.
Methods
The researchers used Cox proportional hazards regression models to determine the association between AE-device therapy and patient outcomes.
- Model I: A basic model without adjustment for other variables.
- Model II: A robust multivariate model adjusted for a comprehensive list of covariates, including age, weight, ethnicity, gender, and clinical markers like the APSIII score, anion gap, glucose levels, and various comorbidities (e.g., renal disease, liver disease, hypertension).
The correction specifically ensures that the reported statistics accurately reflect these models.
Datasets
The specific dataset is not named in the corrigendum itself (it refers back to the original 2022 publication). However, the list of covariates (e.g., APSIII, heart_rate_mean, SpO2_mean) is characteristic of large-scale clinical databases often used in intensive care research, such as MIMIC-III or eICU.
Key Insights and Ideas
- Terminology Precision: In survival analysis, the distinction between Odds Ratios (which describe the odds of an event at a specific time) and Hazard Ratios (which describe the relative risk of an event happening at any time over a period) is crucial. The authors corrected the text to use HR, which is the appropriate metric for Cox regression.
- Consistency in Reporting: The "aha moment" here for researchers is a reminder of the importance of the final proofing stage. An un-updated table can lead to conflicting conclusions within the same document.
- Stability of Findings: Despite the numerical corrections, the core scientific conclusion remains unchanged: anti-embolism devices appear to be a highly effective intervention for reducing mortality in this specific patient cohort.
Key Results
The corrected data shows a statistically significant protective effect of AE-device therapy:
- ICU Mortality (Adjusted): The Hazard Ratio is 0.48 (95% CI: 0.24–0.96, $P = 0.039$). This suggests a 52% reduction in the risk of death while in the ICU for those using the devices.
- 28-Day Mortality (Adjusted): The Hazard Ratio is 0.50 (95% CI: 0.27–0.90, $P = 0.021$). This indicates a 50% reduction in the risk of death within the first 28 days.
- Unadjusted vs. Adjusted: Even before adjusting for complex health variables, the devices showed a strong correlation with survival (Unadjusted HR for ICU mortality was 0.32).
Limitations and Future Work
As this is a corrigendum, it does not propose new future work beyond correcting the record. The authors note that these corrections "do not change the scientific conclusions of the article in any way."
Potential limitations inherent in the original study (though not discussed in this correction) typically include the retrospective nature of database research and the potential for "confounding by indication" (where the healthiest patients are the ones most likely to receive certain preventative therapies). Future prospective trials would be needed to confirm these observational findings.
Summary updated